Stoke Therapeutics, Inc. (STOK) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 2, 2026, Stoke Therapeutics, Inc. (STOK) trades at a price-to-earnings ratio of -22.1x, with a stock price of $36.41 and trailing twelve-month earnings per share of $0.69.
The current P/E is 216% below its 5-year average of 18.9x. Over the past five years, STOK's P/E has ranged from a low of 8.4x to a high of 35.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, STOK trades at a 193% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, STOK trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our STOK DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. RNA and Genome Editing Developers peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
ALNYAlnylam Pharmaceuticals, Inc. | $44B | 142.9 | -Best | +207% |
SLXNWSilexion Therapeutics Ltd. | $64M | 0.0Lowest | -Best | +6436%Best |
DTILPrecision BioSciences, Inc. | $51M | 4.0 | -Best | +107% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $23.50 | $0.67 | 35.1x | +85% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $11.35 | $0.85 | 13.4x | -30% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $6.65 | $0.79 | 8.4x | -56% |
Average P/E for displayed period: 18.9x
See STOK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs STOK Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare STOK vs AGIO
See how STOK stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is STOK stock overvalued or undervalued?
STOK trades at -22.1x P/E, below its 5-year average of 18.9x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does STOK's valuation compare to peers?
Stoke Therapeutics, Inc. P/E of -22.1x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is STOK's PEG ratio?
STOK PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.